197 related articles for article (PubMed ID: 30801534)
41. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
Tang FF; Huang XJ; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang Y; Wang JZ; Yan CH; Sun YQ; Mo XD; Liu KY; Xu LP
Leuk Res; 2016 Aug; 47():8-15. PubMed ID: 27239735
[TBL] [Abstract][Full Text] [Related]
42. Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Zhao XS; Liu KY; Huang XJ
J Mol Diagn; 2020 Feb; 22(2):188-195. PubMed ID: 31751675
[TBL] [Abstract][Full Text] [Related]
43. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis.
Válková V; Polák J; Marková M; Vítek A; Hájková H; Sálek C; Procházka B; Cetkovský P; Trněný M
Clin Transplant; 2013; 27(1):E21-9. PubMed ID: 23231003
[TBL] [Abstract][Full Text] [Related]
44. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379
[TBL] [Abstract][Full Text] [Related]
45. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
[TBL] [Abstract][Full Text] [Related]
46. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
47. Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
Santaliestra M; Garrido A; Carricondo M; Bussaglia E; Pratcorona M; Blanco ML; Gich I; Hoyos M; Esquirol A; García-Cadenas I; Brunet S; Martino R; Sierra J; Nomdedéu JF
Eur J Haematol; 2019 Sep; 103(3):208-214. PubMed ID: 31211880
[TBL] [Abstract][Full Text] [Related]
48. A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.
Niavarani A; Herold T; Reyal Y; Sauerland MC; Buchner T; Hiddemann W; Bohlander SK; Valk PJ; Bonnet D
Br J Haematol; 2016 Feb; 172(3):401-11. PubMed ID: 26597595
[TBL] [Abstract][Full Text] [Related]
49. [Allogeneic hematopoietic stem cell transplantation for the treatment of acute myeloid leukemia with primary thrombocytosis: three cases report and literatures review].
Zong XP; Tang L; Cen JN; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):883-886. PubMed ID: 29166742
[No Abstract] [Full Text] [Related]
50. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG; Egan DN; Bar M; Schmitt TM; McAfee MS; Paulson KG; Voillet V; Gottardo R; Ragnarsson GB; Bleakley M; Yeung CC; Muhlhauser P; Nguyen HN; Kropp LA; Castelli L; Wagener F; Hunter D; Lindberg M; Cohen K; Seese A; McElrath MJ; Duerkopp N; Gooley TA; Greenberg PD
Nat Med; 2019 Jul; 25(7):1064-1072. PubMed ID: 31235963
[TBL] [Abstract][Full Text] [Related]
51. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
[TBL] [Abstract][Full Text] [Related]
52. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
53. [The relationship between WT1 expression level and prognosis in patients of acute T lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation].
Zhang B; Zhao X; Qin Y; Wang Y; Yan C; Xu L; Zhang X; Liu K; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2015 Aug; 36(8):642-6. PubMed ID: 26462631
[TBL] [Abstract][Full Text] [Related]
54. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
55. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements.
Yang H; Huang S; Zhu CY; Gao L; Zhu HY; Lv N; Jing Y; Yu L
Med Sci Monit; 2016 Jul; 22():2315-23. PubMed ID: 27373985
[TBL] [Abstract][Full Text] [Related]
56. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
57. [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis].
Song AX; Yang DL; Wei JL; Yan ZS; Wang M; Jiang EL; Huang Y; Liu QG; Ma QL; Zhai WH; Zhang RL; Feng SZ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):161-6. PubMed ID: 20137139
[TBL] [Abstract][Full Text] [Related]
58. WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia.
Asghari-Ghomi A; Fallahian F; Garavand J; Mohammadi MH
Mol Biol Rep; 2024 Feb; 51(1):244. PubMed ID: 38300383
[TBL] [Abstract][Full Text] [Related]
59. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.
Imahashi N; Suzuki R; Fukuda T; Kakihana K; Kanamori H; Eto T; Mori T; Kobayashi N; Iwato K; Sakura T; Ikegame K; Kurokawa M; Kondo T; Iida H; Sakamaki H; Tanaka J; Kawa K; Morishima Y; Atsuta Y; Miyamura K
Bone Marrow Transplant; 2013 Jan; 48(1):56-62. PubMed ID: 22705800
[TBL] [Abstract][Full Text] [Related]
60. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
